PTC Therapeutics, Inc.: Series E $50M

Posted in I - Series E, Q - 4Q09, R - NORTH EAST, X - CF, X - Hemophilia, X - Muscular Dystrophy, XX - NJ

PTC Therapeutics (South Plainfield, NJ) a clinical-stage small molecule company focused on CF, hemophilia and muscular dystrophy, closed a $50M Series E financing. Participants include The Column Group, Delphi Ventures, CSFB Private Equity, HBM BioVentures and Novo Ventures.
Note: 2009 Year-in-Review Trend Analysis Coming 15 Feb

Feb

2010

Ophthotech Corp.: Series B $30M

Posted in I - Series B, Q - 4Q09, R - NORTH EAST, X - Opthalmology, XX - NJ

Ophthotech (Princeton, NJ) a clinical-stage biopharmaceutical company focused on ophthalmic therapies for wet and dry age-related macular degeneration, closed a $30M Series B financing. Participants include Clarus Ventures, SV Life Sciences, Novo Ventures and HBM BioVentures.

Note: 2009 Year-in-Review Trend Analysis Coming 15 Feb

Jan

2010

Tarsa Therapeutics, Inc.: Series A $24M

Posted in I - Series A, Q - 4Q09, R - NORTH EAST, X - Osteoporosis, XX - NJ

Tarsa Therapeutics (Boonton, NJ) a clinical stage small molecule company focused on osteoporosis closed a $24M Series A financing. Participants include MVM Life Science Partners, Quaker BioVentures and Novo Ventures.

Note: 2009 Year-in-Review Trend Analysis Coming 15 Feb.

Next Entries »

to top of page...